Ally Bridge Group »

Eyepoint Pharmaceuticals shares owned by Ally Bridge Group

Quarter-by-quarter ownership of Eyepoint Pharmaceuticals (EYPT) shares owned by Ally Bridge Group from 13F filings

Historical chart of Ally Bridge Group investment in Eyepoint Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Eyepoint Pharmaceuticals held by Ally Bridge Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Eyepoint Pharmaceuticals by Ally Bridge Group

Quarter filed Position value Share count Share price at filing
2024-12-31 $2.6M 348k 7.45

More positions owned by Ally Bridge Group

Soleno Therapeutics (SLNO)
Replimune Group Call Option (REPL)
Madrigal Pharmaceuticals (MDGL)
Compass Pathways Sponsored Ads (CMPS)
Atai Beckley Nv SHS (ATAI)
Ascendis Pharma A/s - Sponsored Adr (ASND)
Lenz Therapeutics (LENZ)
Taysha Gene Therapies Com Shs (TSHA)
Amylyx Pharmaceuticals (AMLX)
Eupraxia Pharmaceuticals (EPRX)
Praxis Precision Medicines I Com New Call Option (PRAX)
Monopar Therapeutics Com New (MNPR)
Arcutis Biotherapeutics (ARQT)
Mind Medicine Mindmed Com New (MNMD)
Tarsus Pharmaceuticals (TARS)

View all positions for Ally Bridge Group

Top funds holding Eyepoint Pharmaceuticals

Cormorant Asset Management
Suvretta Capital Management
Adage Capital Partners GP
BlackRock
Federated Investors
Franklin Resources
Vanguard Group
TCG Crossover Management
Citadel Advisors
Paradigm Biocapital Advisors
OrbiMed Advisors
Geode Capital Management
Goldman Sachs Group
State Street Corporation
Essex Woodlands Health Ventures

View all funds holding Eyepoint Pharmaceuticals